Table 3.
Cell Line | Tumor Type | IC50 (>M)a
|
|||
---|---|---|---|---|---|
6i | 6p | 6t | 25c | ||
DU145 | Prostate | 0.075 | 0.050 | 0.008 | 0.15 |
K562 | Leukemia | 0.075 | 0.015 | 0.003 | 0.01 |
LNCAP | Prostate | 0.100 | 0.050 | 0.008 | 0.10 |
PC3 | Prostate | 0.100 | 0.025 | 0.008 | N/D |
SK-MEL-28 | Melanoma | 0.050 | 0.025 | 0.008 | N/D |
MCF-7 | Breast | 0.050 | 0.025 | 0.004 | 0.08 |
SK BR-3 | Breast | 0.050 | 0.025 | 0.004 | N/D |
BT474 | Breast | 0.250 | 0.025 | 0.010 | 0.15 |
BT20 | Breast | 0.250 | 0.250 | 0.008 | 0.10 |
T47D | Breast | 0.100 | 0.025 | 0.008 | N/D |
A431 | Epidermoid | 0.030 | 0.600 | 0.005 | 0.15 |
HCT116 | Colo-Rectal | 0.100 | 0.010 | 0.004 | N/D |
HCT15 | Colo-Rectal | 0.100 | 0.025 | 0.008 | 0.20 |
SKOV3 | Ovarian | 0.100 | 0.025 | 0.008 | N/D |
OVCAR3 | Ovarian | 0.100 | 0.100 | 0.004 | N/D |
H187 | NSCLC | 0.100 | 0.010 | 0.004 | N/D |
N417 | SCLC | 0.050 | 0.010 | 0.004 | 0.03 |
RF-48 | Gastric | 0.025 | 0.010 | 0.004 | N/D |
RF-1 | Gastric | 0.050 | 0.010 | 0.004 | N/D |
MIAPaCa2 | Pancreatic | 0.100 | 0.010 | 0.004 | 0.08 |
H80 | Glioma | 0.100 | 0.025 | 0.004 | N/D |
MES-SA | Uterine | 0.050 | 0.025 | 0.004 | N/D |
NAMALWA | Lymphocytic | 0.100 | 0.025 | 0.008 | N/D |
DAUDI | Lymphocytic | 0.100 | 0.025 | 0.008 | 0.03 |
MOLT-4 | Lymphocytic | 0.100 | 0.025 | 0.008 | 0.03 |
U87 | Gliomab | 0.229 | 0.026 | 0.009 | 0.09 |
GI50 (growth inhibitory concentration-50%). Cells were treated with 6i, 6p, 6t and 25c in a 96 h dose response assay. The GI50 concentration (μM) was determined from duplicate cell counts using a Hemocytometer following trypsinization and trypan blue staining.
Values are IC50 as measured by SRB assay. ND = not determined